Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
Caroline E. Nunes‐Xavier, J.C. Angulo, Rafael Pulido, et al.
Current Urology Reports (2019) Vol. 20, Iss. 1
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

PD-1/PD-L1 pathway: current researches in cancer.
Yanyan Han, Dandan Liu, Lianhong Li
PubMed (2020) Vol. 10, Iss. 3, pp. 727-742
Closed Access | Times Cited: 1360
Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors
Shovan Dutta, Anirban Ganguly, Kaushiki Chatterjee, et al.
Biology (2023) Vol. 12, Iss. 2, pp. 218-218
Open Access | Times Cited: 74
Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers
Sean R. Williamson, Anthony J. Gill, Pedram Argani, et al.
The American Journal of Surgical Pathology (2020) Vol. 44, Iss. 7, pp. e47-e65
Open Access | Times Cited: 88
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications
Miguel Á. Ortega, Diego Liviu Boaru, Diego De León-Oliva, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 8, pp. 987-1000
Closed Access | Times Cited: 13
The Changing Therapeutic Landscape of Metastatic Renal Cancer
J.C. Angulo, Oleg Shapiro
Cancers (2019) Vol. 11, Iss. 9, pp. 1227-1227
Open Access | Times Cited: 64
The role of cancer-associated fibroblasts in renal cell carcinoma. An example of tumor modulation through tumor/non-tumor cell interactions
Peio Errarte, Gorka Larrinaga, José I. López
Journal of Advanced Research (2019) Vol. 21, pp. 103-108
Open Access | Times Cited: 57
Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
Gorka Larrinaga, Jon Danel Solano-Iturri, Peio Errarte, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 667-667
Open Access | Times Cited: 42
Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement
Riccardo Ray Colciago, Irene Fischetti, Carlotta Giandini, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 2, pp. 135-145
Open Access | Times Cited: 18
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
Matthew D. Tucker, Brian I. Rini
Cancers (2020) Vol. 12, Iss. 9, pp. 2662-2662
Open Access | Times Cited: 41
EMT-induced immune evasion: connecting the dots from mechanisms to therapy
Sikiru O. Imodoye, Kamoru A. Adedokun
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 4265-4287
Closed Access | Times Cited: 14
High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment
Lissete Sánchez‐Magraner, James Miles, Claire L. Baker, et al.
Cancer Research (2020) Vol. 80, Iss. 19, pp. 4244-4257
Open Access | Times Cited: 39
lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System
Dominik A. Barth, Jaroslav Juráček, Ondřej Slabý, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2148-2148
Open Access | Times Cited: 37
Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging
Brian Effer, Isabela Perez, Daniel Ulloa, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 2086-2086
Open Access | Times Cited: 12
Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15233-15233
Open Access | Times Cited: 12
Diagnosis and grading of vesicoureteral reflux on voiding cystourethrography images in children using a deep hybrid model
Yeşim Eroğlu, Kadir Yıldırım, Ahmet Çınar, et al.
Computer Methods and Programs in Biomedicine (2021) Vol. 210, pp. 106369-106369
Closed Access | Times Cited: 26
Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
Faisal K. Alkholifi, Rana M. Alsaffar
Medicina (2022) Vol. 58, Iss. 11, pp. 1572-1572
Open Access | Times Cited: 17
Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy - a review
Marek Zdrenka, Adam Kowalewski, Navid Ahmadi, et al.
Biomolecules and Biomedicine (2023)
Open Access | Times Cited: 10
Knowledge mapping of immunotherapy in cervical carcinoma: a bibliometric analysis (2000-2023)
Ling Song, Xinmei Liang, Min Zhu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 3
Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering
Tien‐Sheng Tseng, Chao-Chang Lee, P. Chen, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 5, pp. 1615-1627
Closed Access | Times Cited: 3
Immunotherapy of Clear-Cell Renal-Cell Carcinoma
Sophie Grigolo, Luis Filgueira
Cancers (2024) Vol. 16, Iss. 11, pp. 2092-2092
Open Access | Times Cited: 3
The role of ncRNAs and exosomes in the development and progression of endometrial cancer
Julia Niebora, Sławomir Woźniak, Dominika Domagała, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Emerging Immune Checkpoint Inhibitors for the Treatment of Oropharyngeal Squamous Cell Carcinoma
Pandiselvi Ravi, Shyamaladevi Babu
Oral Oncology Reports (2024), pp. 100650-100650
Open Access | Times Cited: 3
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
Nicole Brighi, Alberto Farolfi, Vincenza Conteduca, et al.
Cancers (2019) Vol. 11, Iss. 12, pp. 1935-1935
Open Access | Times Cited: 27
Cell Motility and Cancer
Ildefonso M. De la Fuente, José I. López
Cancers (2020) Vol. 12, Iss. 8, pp. 2177-2177
Open Access | Times Cited: 27
Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
Peng Ding, Z. Ma, Yizeng Fan, et al.
Genes & Diseases (2022) Vol. 10, Iss. 3, pp. 848-863
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top